Publications by authors named "J Voegeler"
Purpose: Ranibizumab monotherapy showed stronger effects on area of retinal neovascularization (NV) reduction while offering better visual acuity (VA) results than panretinal laser photocoagulation (PRP) monotherapy during the first 12 months of the PRIDE study. The second year of PRIDE was an observational, non-interventional follow-up, performed to evaluate long-term anatomical and functional outcomes in proliferative diabetic retinopathy (PDR) patients under real-life conditions, prior to the approval of ranibizumab for PDR.
Methods: Seventy-three PDR patients (28 from the ranibizumab group; 20 from the PRP group; 25 from the combination group) were included in the observational follow-up phase and treated at the investigators discretion.
Aim: The prospective, noninterventional OCEAN study assessed the safety of intravitreal ranibizumab injections for treatment of neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion under real-world conditions in Germany.
Methods: Adults receiving ≥1 ranibizumab (0.5 mg) injections were recruited by 369 ophthalmologists and followed for 24 months.
Article Synopsis
- The ORCA module of the OCEAN study assessed how well clinicians in Germany interpreted SD-OCT images for neovascular age-related macular degeneration (nAMD) and made treatment decisions over a 24-month period.
- 2286 SD-OCT scans from 205 eyes were independently reviewed for indications of choroidal neovascularization (CNV) activity, revealing a 74.9% agreement rate between clinicians and reading centers (RCs).
- Despite detecting CNV activity in a substantial number of scans, clinicians initiated treatment in only 35.5% of those cases, leading to concerns about visual acuity decline due to potential undertreatment and the need for better decision-making in therapy based on SD-OCT
Purpose: Panretinal photocoagulation (PRP) is the current standard of care in proliferative diabetic retinopathy (PDR). However, treatment with anti-vascular endothelial growth factor agents might offer better patient outcomes with fewer side-effects. The PRIDE study aimed to assess the efficacy and safety of ranibizumab with or without PRP compared with PRP alone in patients with PDR.
View Article and Find Full Text PDFIntroduction: The prospective, non-interventional OCEAN study examined the use of intravitreal ranibizumab injections for the treatment of diabetic macular oedema (DME) in a real-world setting in Germany.
Methods: Adults with DME receiving ≥ 1 ranibizumab (0.5 mg) injections were recruited by 250 ophthalmologists.